2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Jonathan Strosberg, MD, discusses retreatment with Lutathera in advanced neuroendocrine tumors.
Jonathan Strosberg, MD, associate professor, Moffitt Cancer Center, discusses retreatment with Lutathera (lutetium 177-dotatate) in advanced neuroendocrine tumors (NETs).
Results presented during the 2020 NANETs Virtual Symposium meeting showed an encouraging median progression-free survival of about 12.5 months after retreatment with Lutathera, says Strosberg.
Typically, patients receive 2 additional cycles of Lutathera and, in cases of progression, another 2 cycles are administered, Strosberg explains. Notably, patients should not receive more than 8 cycles of retreatment, as it will increase their risk of developing resistance.
The results suggest that retreatment with Lutathera appears to be effective and safe, although additional research is warranted, Strosberg concludes.